Initiation of epoetin-α therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: An open-label, multicenter study with randomized and nonrandomized treatment arms

Cancer

Volumn 115, Issue 5, 2009, Pages 1121-1131

  Glaspy, John A ^a   Charu, Veena ^b   Luo, Donghan ^c   Moyo, Victor ^c   Kamin, Marc ^c   Wilhelm, Francois E ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Pacific Cancer Medical Center   (United States)

^c Ortho Biotech Products LP   (United States)

Author keywords

Anemia; Antineoplastic agents; Blood transfusion; Drug administration schedule; Epoetin ; Hemoglobins

Indexed keywords

ANTINEOPLASTIC AGENT; FERROUS SULFATE; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLOOD PRESSURE MEASUREMENT; BLOOD TRANSFUSION; BONE PAIN; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER SCREENING; CAUSE OF DEATH; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EARLY INTERVENTION; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL TUMOR; HEAD AND NECK CANCER; HEADACHE; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPESTHESIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; INJECTION SITE PAIN; INSOMNIA; IRON THERAPY; JUGULAR VEIN THROMBOSIS; LEUKOPENIA; LIMB PAIN; LOADING DRUG DOSE; LUNG ARTERY THROMBOSIS; LUNG EMBOLISM; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NON CARDIAC CHEST PAIN; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PERIPHERAL SENSORY NEUROPATHY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; SARCOMA; SHOULDER PAIN; SORE THROAT; THROMBOCYTOPENIA; THROMBOEMBOLISM; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UROGENITAL TRACT CANCER; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; EPOETIN ALFA; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 61449231719     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24127     Document Type: Article

References (15)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616-1634.
2. PROCRIT® (Epoetin alfa) [package insert], Raritan, NJ: Ortho Biotech Products LP; August 2008.
3. EPOGEN® (Epoetin alfa) [package insert]. Thousand Oaks, CA: Amgen, Inc; August 2008.
4. Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther. 2006;28:801-831.
5. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007;11:1-220.
6. Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS. Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of 4 observational studies. Clin Ther. 2006;28:1701-1708.
7. Henry DH, Gordan LN, Charu V, et al. Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia. Curr Med Res Opin. 2006;22:1403-1413.
8. Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Oncologist. 2004;9:90-96.
9. Montoya VP, Xie J, Williams D, Woodman RC, Wilhelm FE. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy. Support Care Cancer. 2007; 15: 1385-1392.
10. Steensma DP, Molina R, Sloan JA, et al. Phase III study of 2 different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol. 2006;24:1079-1089.
11. Mark TL, McKenzie RS, Fastenau J, Piech CT. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. Curr Med Res Opin. 2005;21:1347-1354.
12. ARANESP®(Darbepoetin alfa) [package insert]. Thousand. Oaks, CA: Amgen, Inc; August 2008.
13. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997:13:63-74.
14. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004;40:2201-2216.
15. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002;100:2303-2320.